HPLC quantification of perphenazine in sheep plasma: Application to a pharmacokinetic study

Development, validation, and application of a simple UPLC-MS/MS method for simultaneous quantification of five traditional antipsychotics in human plasma

A UPLC-MS/MS method was developed to determine the levels of five traditional antipsychotics (APs) (chlorprothixene, perphenazine, fluphenazine, thioridazine, and promethazine) in human plasma with carbamazepine as the internal standard. Samples were extracted using simple liquid-liquid extraction (ethyl acetate/methyl tert-butyl ether, 2:3 v/v); then the analytes were subjected to gradient elution chromatography with a mobile phase composed of 0.1% formic acid in water and acetonitrile. The analytes were separated using a Waters XBridge BEH C₁₈ column (100 × 2.1 mm, 2.5 μm). The linear ranges of chlorprothixene, perphenazine, fluphenazine, thioridazine, and promethazine are 2-250 ng/mL, r > 0.995. The limit of quantitation is 2 ng/mL, and the limit of detection is in the range of 0.1-0.5 ng/mL. The inter-day and intra-day relative standard deviations are less than 10%, and the relative errors are in the range of -5.70 to 7.20%. The recoveries of the five drugs are in the range of 70-109%. The results of methodology verification indicate that this method is simple, economical, sensitive, and suitable for the simultaneous quantification of five traditional APs in human plasma.

Preparation, characterization, and in vivo evaluation of perphenazine-loaded nanostructured lipid carriers for oral bioavailability improvement

OBJECTIVE

The main scope of the present investigation was to improve the bioavailability of perphenazine (PPZ) by incorporating it into the nanostructured lipid carriers (NLCs).

SIGNIFICANCE

As a result of lipophilic nature and poor aqueous solubility, as well as extensive hepatic metabolism, PPZ has low systemic bioavailability via the oral route. NLCs have shown potentials to surmount the oral delivery drawbacks of poorly water-soluble drugs.

METHODS

The PPZ-NLCs were prepared by the emulsification-solvent evaporation method and subjected for particle size, zeta potential, and entrapment efficiency (EE) analysis. The optimized NLCs were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and powder X-ray diffractometry (PXRD). Besides, in vitro release behavior, storage stability, and pharmacokinetic studies followed by a single-dose oral administration in rats were performed.

RESULTS

Optimized PPZ-NLCs showed a particle size of less than 180 nm with appropriate EE of more than 95%. Microscopic images captured with SEM and TEM exhibited that NLCs were approximately spherical in shape. DSC and PXRD analysis confirmed reduced crystallinity of PPZ after incorporation in NLCs. FTIR spectra demonstrated no chemical interactions between PPZ and NLC components. In vitro release studies confirmed the extended-release properties of NLC formulations. PPZ-NLCs exhibited good stability at 4 °C within three months. The oral bioavailability of NLC-6 and NLC-12 was enhanced about 3.12- and 2.49-fold, respectively, compared to the plain drug suspension.

CONCLUSION

NLC can be designated as an effective nanocarrier for oral delivery of PPZ.

Spectrophotometric determination of perphenazine with the detection system of potassium ferricyanide-Fe(III) in pharmaceutical and serum samples

In this paper, a novel spectrophotometric method has been established to determine perphenazine using the detection system of potassium ferricyanide-Fe(III). In the presence of potassium ferricyanide, it has been demonstrated that Fe(III) is reduced to Fe(II) by perphenazine at pH 4.0. In addition, soluble prussian blue (KFe(III)[Fe(II)(CN)(6)]) is produced by the reaction between the in situ formed Fe(II) and potassium ferricyanide. The absorbance of soluble prussian blue is measured at the absorption maximum of 735 nm, and the amount of perphenazine can be calculated based on this absorbance. The absorbance is linear to perphenazine concentration in the ranges of 0.05-25.00 microg/mL with correlation coefficients of 0.9997, and the linear regression equation is A = 0.0069 + 0.1285C (microg/mL). The detection limit (3sigma/k) is 0.049 microg/mL, and the relative standard deviation (R.S.D.) is 0.86% (n = 11). Moreover, the apparent molar absorption coefficient of indirect determination of perphenazine is 5.2 x 10(4) L/mol cm. The parameters with regard to determination are optimized, and the reaction mechanism is discussed. This method has been successfully applied to the determination of perphenazine in pharmaceutical and serum samples. Analytical results obtained with this novel assay are satisfactory.